Anaplastic lymphoma kinase tyrosine kinase inhibitor-induced hepatic failure in lung cancer patients: A study of signal mining and analysis of the FDA adverse event reporting system database

导出原文传递

翻译打印收藏纠错

作者： Zhou, Ziye ^[1] ; Wang, Chenxiang ^[2] ; Ying, Lili ; Jin, Mi ; Zhang, Fangfang ; Shi, Dawei

作者单位： Wenzhou Med Univ, Affiliated Hosp 1, Dept Pathol, Wenzhou, Peoples R China ^[1] Wenzhou Med Univ, Affiliated Hosp 1, Dept Pharm, Wenzhou 325000, Zhejiang, Peoples R China ^[2]

关键词 alectinib anaplastic lymphoma kinase tyrosine kinase inhibitors ceritinib crizotinib hepatic failure hepatic necrosis hepatitis fulminant lung cancer

发布时间 2021-09-27

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Journal of Clinical Pharmacy and Therapeutics

2021年46卷4期

1148-1154页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Anaplastic lymphoma kinase tyrosine kinase inhibitor-induced hepatic failure in lung cancer patients: A study of signal mining and analysis of the FDA adverse event reporting system database

Journal of Clinical Pharmacy and Therapeutics

相似文献

Journal of Clinical Pharmacy and Therapeutics

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Anaplastic lymphoma kinase tyrosine kinase inhibitor-induced hepatic failure in lung cancer patients: A study of signal mining and analysis of the FDA adverse event reporting system database

Journal of Clinical Pharmacy and Therapeutics

相似文献

Journal of Clinical Pharmacy and Therapeutics

相关期刊

检索历史清除